Skip to main content

Table 1 (abstract A24). Characteristics of Children with Juvenile Idiopathic Arthritis and Uveitis

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

N (%), unless indicated

Overall

JIAa alone (n = 22)

JIA-Ub (n = 22)

Other Uc (n = 18)

Characteristics

    

Demographics

    

Age, Mean (SD)d

13.0 (3.3)

12.9 (2.8)

12.6 (3.4)

13.5 (3.9)

Gender, Male

14 (22.6)

2 (9.1)

4 (18.2)

8 (44.4)

Race

 White

53 (85.5)

21 (95.5)

20 (90.9)

12 (66.7)

 African American

5 (8.1)

1 (4.5)

1 (4.5)

3 (16.7)

 American Indian/Alaskan Native

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Asian

1 (1.6)

0 (0.0)

1 (4.5)

0 (0.0)

 Multi-racial

1 (1.6)

0 (0.0)

0 (0.0)

1 (5.6)

 Unknown/Declined

2 (3.2)

0 (0.0)

0 (0.0)

2 (11.1)

Ethnicity, Hispanic

1 (1.6)

0 (0.0)

1 (4.7)

0 (0.0)

JIA Characteristics

 Age at Diagnosis, Mean (SD)

6.3 (4.6)

7.7 (4.3)

4.9 (4.2)

 

 Duration of Disease, years, Mean (SD)

6.5 (4.3)

5.2 (3.7)

7.7 (4.7)

 

 JIA Subtype

  Oligoarticular Persistent

14 (31.8)

10 (45.5)

4 (18.2)

 

  Oligoarticular Extended

9 (20.5)

3 (13.6)

6 (27.3)

 

  Polyarticular RF(-)

17 (38.6)

9 (40.9)

8 (36.4)

 

Uveitis Characteristics

 Age at Diagnosis, Mean (SD)

8.4 (4.5)

 

6.1 (4.0)

11.4 (3.0)

 Duration of Disease, years, Mean (SD)

4.8 (4.3)

 

6.4 (4.7)

2.8 (2.8)

 Bilateral Disease

  

17 (77.2)

12 (66.7)

 Anterior Chamber Cells >0.5+

  

1 (4.6)

2 (11.1)

 Visual Acuity 20/50 or worse

  

0 (0.0)

0 (0.0)

 Location

    

  Anterior

  

22 (100.0)

13 (72.2)

  Intermediate

  

1 (4.5)

3 (1.7)

  Posterior

  

0 (0.0)

1 (5.5)

  Panuveitis

  

0 (0.0)

2 (11.1)

Ocular Complications, ever

 Glaucoma or Glaucoma Suspect

21 (33.9)

 

11 (50.0)

10 (55.6)

 Cataracts

16 (25.8)

 

10 (45.5)

6 (33.3)

 Synechiae

11 (17.7)

 

8 (36.4)

3 (16.7)

 Band Keratopathy

4 (6.5)

 

1 (4.5)

3 (16.7)

 Amblyopia

3 (4.8)

 

2 (9.1)

1 (5.6)

 Cystoid Macular Edema

1 (1.6)

 

1 (4.5)

0 (0.0)

 Othere

1 (1.6)

 

0 (0.0)

1 (5.6)

Treatment, at time of visit

 Steroid drops

24 (38.7)

 

11 (50.0)

13 (72.2)

 Dilating drops

2 (3.2)

 

2 (9.1)

0 (0.0)

 IOP-lowering dropsf

5 (8.1)

 

1 (4.5)

4 (22.2)

 Methotrexate oral

12 (19.4)

5 (22.7)

5 (22.7)

2 (11.1)

 Methotrexate SQ

10 (16.1)

3 (13.6)

4 (18.2)

3 (16.7)

 Mycophenolate

2 (3.2)

0 (0.0)

1 (4.5)

1 (5.6)

 Etanercept

4 (6.5)

4 (18.2)

0 (0.0)

0 (0.0)

 Infliximab

12 (19.4)

1 (4.5)

6 (27.3)

5 (27.8)

 Adalimumab

9 (14.5)

2 (9.1)

6 (27.3)

1 (5.6)

 Abatacept

1 (1.6)

0 (0.0)

1 (4.5)

0 (0.0)

 Tocilizumab

7 (11.3)

3 (13.6)

4 (18.2)

0 (0.0)

  1. aJIA: juvenile idiopathic arthritis; bJIA-U: JIA-associated uveitis; cOther U: all other uveitis not associated with JIA; d SD: standard deviation; eOther complications include: vitreous hemorrhage, optic disc edema, aphakia, choroidal neovascular membranes, choriorential scare, retinal neovascularization, retinal detachment, keratic precipitates, peri retinal fibrosis, floaters, blindness, ocular hypertension; fIOP: Intraocular pressure